Chinese cell therapy developer JW Therapeutics has raised HK$2.325 billion (nearly $300 million) in an initial public offering (IPO) in Hong Kong, on Tuesday, to finance the firm’s efforts to obtain China’s first CAR-T product approval.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
